GDC 0310

Drug Profile

GDC 0310

Alternative Names: GDC-0310; RG 6029

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xenon Pharmaceuticals
  • Developer Genentech; Xenon Pharmaceuticals
  • Class Analgesics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 07 Nov 2017 Genentech announces that based on results from its preclinical toxicology studies GDC 0310 will not enter a phase II clinical trial in the first quarter of 2018
  • 01 Jun 2016 Genentech completes a phase I trial in health voluneers in USA (NCT02742779)
  • 15 Mar 2016 Xenon Pharmaceuticals and Genentech extends its agreement to co-develop GDC 0310 for Pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top